WOOF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Petco Health and Wellness Company Inc (WOOF) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company's financial performance has been weak, and there are no strong technical or proprietary trading signals to support an immediate purchase. While some analysts have upgraded their ratings and raised price targets, the overall sentiment remains mixed, and the stock's recent price trend and financials do not present a compelling long-term growth story.
The stock is currently trading at $2.68, down -2.36% in the regular market. The MACD is negative and expanding downward, indicating bearish momentum. The RSI is neutral at 36.809, and moving averages are converging, showing no clear trend. Support levels are at $2.799 and $2.551, while resistance levels are at $3.2 and $3.601. Overall, the technical indicators suggest a weak price trend.
Some analysts have raised price targets, with Jefferies upgrading the stock to Buy and highlighting Petco's growth initiatives and liquidity improvements. Additionally, the company has shown some progress in executing growth plans for 2026.
The company's Q4 financials showed significant declines in revenue (-2.38% YoY), net income (-81.39% YoY), and EPS (-80.00% YoY). Gross margin also dropped by -32.03%. The stock's price trend is weak, and there are no significant hedge fund or insider trading activities to support a bullish case. Options data indicates bearish sentiment with a high put-call volume ratio (2.82).
In Q4 2026, Petco reported a revenue decline of -2.38% YoY to $1.515 billion. Net income dropped significantly by -81.39% YoY to -$2.575 million. EPS fell by -80.00% YoY to -$0.01. Gross margin decreased to 25.8%, down -32.03% YoY. The financial performance indicates a challenging period for the company.
Analyst sentiment is mixed. Jefferies upgraded the stock to Buy with a price target of $5, citing growth initiatives and liquidity improvements. However, Evercore ISI and Goldman Sachs lowered their price targets, and the overall ratings remain neutral to slightly positive. The average price target is in the $3-$5 range, which is modestly above the current price but does not indicate strong upside potential.
